0,76 €
0,28 %heute
L&S, 21. Februar, 09:07 Uhr
ISIN
US49372L1008
Symbol
KZR
Berichte
Sektor
Industrie

Kezar Life Sciences Inc Aktie News

Positiv
InvestorPlace
19 Tage alt
In stock markets, uncovering penny stocks with a 10X boost potential is rare, but possible. This requires the identification of extraordinary growth potency.
Positiv
InvestorPlace
2 Monate alt
In the labyrinth of the stock market, discovering penny growth stocks often promises exhilarating prospects. This article navigates through the tumultuous waves of investment options, spotlighting three promising penny stocks.
Neutral
PRNewsWire
3 Monate alt
NEW YORK , Dec. 4, 2023 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Kezar Life Sciences, Inc. (NASDAQ: KZR) on behalf of the company's shareholders. The investigation seeks to determine whether Kezar Life Sciences's directors breached their fiduciary duties in connection with recent corporate actions that have caused a decline in Kezar Life Sciences's stock price.
Neutral
Business Wire
3 Monate alt
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023...
Neutral
Business Wire
3 Monate alt
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update.
Neutral
Business Wire
4 Monate alt
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation Committee of the company's Board of Directors granted one employee a nonqualified stock option to purchase 50,000 shares of its common stock with an exer...
Neutral
Business Wire
4 Monate alt
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation Committee of the company's Board of Directors granted one employee a nonqualified stock option to purchase 18,000 shares of its common stock with an exer...
Neutral
Business Wire
5 Monate alt
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced it has initiated a strategic restructuring program to prioritize long-term growth and focus its resources on its clinical-stage programs. The strategic realignment is expected...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen